about
Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.Current therapy of myelodysplastic syndromesMyelodysplastic syndromes: toward a risk-adapted treatment approach.Standardizing the initial evaluation for myelodysplastic syndromes.Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.Fungal Ribotoxins: A Review of Potential Biotechnological Applications.Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
P2860
Q33408873-2D6E1D84-1688-4A59-A886-8F4F75B928BCQ34013796-CA312024-5DCD-4F1D-90B2-ED3A530E34A9Q38149315-AD49CF3B-2FA2-4882-9867-AC7E77B5E31BQ38157706-EAD1C09F-DB04-4CAD-A6BB-D35860A5BE27Q38195796-3CCC6C72-93AD-4265-8D3C-83EEC8FE753FQ39147928-7991F23C-2FBE-47B0-AD49-A57F9620F25CQ44850006-68F2B161-9D1A-4EB1-BC12-3C4750FBCF43Q50556796-0B589906-5333-4D2A-B58D-FC4670ADB769
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The 5q- syndrome: biology and treatment.
@en
The 5q- syndrome: biology and treatment.
@nl
type
label
The 5q- syndrome: biology and treatment.
@en
The 5q- syndrome: biology and treatment.
@nl
prefLabel
The 5q- syndrome: biology and treatment.
@en
The 5q- syndrome: biology and treatment.
@nl
P2093
P2860
P1476
The 5q- syndrome: biology and treatment.
@en
P2093
Alan F List
Eric Padron
Rami Komrokji
P2860
P2888
P304
P356
10.1007/S11864-011-0165-1
P577
2011-12-01T00:00:00Z